Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tretinoin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Tretinoin. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-017201-11 Sponsor Protocol Number: CT10025VER Start Date*: 2010-06-15
    Sponsor Name:VERISFIELD (UK) LTD, GREEK BRANCH
    Full Title: MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARATIVE STUDY WITH THE REFERENCE PRODUCTS, FOR ASSESSMENT OF THERAPEUTIC SUPERIORITY OF THE COMBINATION CLINDAMYCIN-TRETINOIN/VERISFIELD, GEL, (1.0+0.025)%...
    Medical condition: ACNE (ACNE VULGARIS)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022918-15 Sponsor Protocol Number: 7001‐G2HP‐07‐02 Start Date*: 2012-03-07
    Sponsor Name:Dow Pharmaceutical Sciences
    Full Title: Multi-centre, randomized, double-blind, active- and vehicle-controlled trial to compare the efficacy and safety of tretinoin clindamycin phosphate gel to clindamycin phosphate gel alone, tretinoin ...
    Medical condition: Treatment of acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-003070-23 Sponsor Protocol Number: CLITRETVER Start Date*: 2023-01-27
    Sponsor Name:Verisfield S.M.S.A.
    Full Title: A multicenter, randomized, double-blind, parallel, three-arm, active- and placebo-controlled therapeutic equivalence for the comparison of clindamycin + tretinoin/Verisfield gel (1+0.025)% with Acn...
    Medical condition: Acne Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022911-20 Sponsor Protocol Number: 7001‐G2HP‐06‐02 Start Date*: 2012-03-07
    Sponsor Name:Dow Pharmaceutical Sciences
    Full Title: A Multi-Center, Phase 3, Randomized, Double-Blind, 4-Arm Clinical Trial to Compare the Safety and Efficacy of Clin-RA Gel vs. Clindamycin Phosphate 1.2% Gel vs. Tretinoin 0.025% Gel vs. Clin-RA Gel...
    Medical condition: Treatment of acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-003153-39 Sponsor Protocol Number: SDRFTT Start Date*: 2021-12-01
    Sponsor Name:Bispebjerg Hospital, Department of Dermatology
    Full Title: Treatment of striae distensae with fractional radiofrequency and topical tretinoin: An intra-individual study with blinded outcome assessment
    Medical condition: Striae Distensae
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10057065 Striae distensae LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-000093-23 Sponsor Protocol Number: H 565000 - 0620 Start Date*: 2007-05-18
    Sponsor Name:Almirall Hermal GmbH
    Full Title: Clinical trial to investigate clinical efficacy and tolerability of Tretinoin in actinic keratosis
    Medical condition: actinic keratosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000614 Actinic keratosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022912-37 Sponsor Protocol Number: MP‐1501‐01 Start Date*: 2012-03-07
    Sponsor Name:Medicis Pharmaceutical Corporation [...]
    1. Medicis Pharmaceutical Corporation
    2. Dow Pharmaceutical Sciences
    Full Title: Multi-centre, open-label, long-term safety trial to assess the long-term safety of tretinoin clindamycin phosphate gel in patients from 12 to less than 18 years of age with acne vulgaris.
    Medical condition: Treatment of Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-014550-14 Sponsor Protocol Number: DPSI-Acanya-P4-02 / 290622BS Start Date*: 2009-09-25
    Sponsor Name:Dow Pharmaceutical Sciences, Inc on behalf of Coria Laboratories
    Full Title: A single center, randomized, controlled study to determine the irritant potential of topical acne formulations on intact healthy skin on the back following repeated application during a 21-day trea...
    Medical condition: Cumulative irritation test
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022919-20 Sponsor Protocol Number: MP-1501-02 Start Date*: 2012-03-07
    Sponsor Name:Dow Pharmaceutical Sciences [...]
    1. Dow Pharmaceutical Sciences
    2. Medicis Pharmaceutical Corporation
    Full Title: Multi-centre, randomized, double-blind trial to compare the efficacy and safety of tretinoin clindamycin phosphate gel to clindamycin phosphate gel alone in the treatment of acne vulgaris in patien...
    Medical condition: Treatment of Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002154-23 Sponsor Protocol Number: UKM_04_12_TCP_ATRA_AML Start Date*: 2014-08-28
    Sponsor Name:Martin-Luther-University Halle-Wittenberg
    Full Title: Phase I/II pilot trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in patients with relapsed or refractory acute myeloid leukemia (AML) when no intensive treatment is possible
    Medical condition: relapse or refractory AML in patients unfit for an intensive treatment
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003977-24 Sponsor Protocol Number: MK-3475-02B Start Date*: 2020-03-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
    Full Title: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Prematurely Ended) IT (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002699-26 Sponsor Protocol Number: PREFECT Start Date*: 2015-10-08
    Sponsor Name:GWT-TUD GmbH
    Full Title: Pilot study of tolerability and effectivity following application of two combination topical acne products clindamycin 1% and 0.025% tretinoin gel (Acnatac® Gel), adapalen 0,1% and benzoyl peroxide...
    Medical condition: acne vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004231-23 Sponsor Protocol Number: 274948 Start Date*: 2020-05-29
    Sponsor Name:Queen Mary University of London
    Full Title: Phase IIb randomised clinical trial repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancer
    Medical condition: Pancreatic cancer - locally advanced
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-005500-14 Sponsor Protocol Number: MZ-ATRACTION/ML 20804 Start Date*: 2007-09-05
    Sponsor Name:Universitätsmedizin der Johannes-Gutenberg Universität Mainz
    Full Title: A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGA...
    Medical condition: chronic HCV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019183 HCV LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002383-40 Sponsor Protocol Number: ICC_APL_Study_02 Start Date*: 2019-03-20
    Sponsor Name:AIEOP- Associazione Italiana Ematologia Oncologia Pediatrica
    Full Title: Treatment study for children and adolescents with Acute Promyelocytic Leukemia
    Medical condition: acute promyelocytic leukemia (APL) in children and adolescents
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006379-65 Sponsor Protocol Number: 02A801 Start Date*: 2008-10-27
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease
    Medical condition: sperimentation only in patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005597-43 Sponsor Protocol Number: RG_06-280 Start Date*: 2008-02-04
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. Birmingham Heartlands Hospital
    Full Title: Topical Retinoids and Diabetic Neuropathic Ulceration
    Medical condition: The overall goal of the proposal is to assess the capacity of topical retinoid treatment to induce changes in connective tissue metabolism (i.e., increased collagen production and decreased elabora...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050712 Vitamin A LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000421-39 Sponsor Protocol Number: AMLSG26-16/AML-ViVA Start Date*: 2017-02-03
    Sponsor Name:University Hospital Regensburg represented by Kaufmännischer Direktor
    Full Title: Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients >=60 years with acute myelo...
    Medical condition: acute myeloid leukemia refractory to standard induction chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004606-24 Sponsor Protocol Number: 04.168-11 Start Date*: 2005-01-24
    Sponsor Name:Fujisawa GmbH
    Full Title: A randomized, open-label, monocentric clinical phase I/IV study in healthy human volunteers to evaluate the skin tolerability and cosmetic acceptance of three marketed anti-acne drugs (Differin® Cr...
    Medical condition:
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023409-37 Sponsor Protocol Number: AMLSG_15-10 Start Date*: 2011-03-02
    Sponsor Name:University Hospital Ulm
    Full Title: Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM...
    Medical condition: Adult patients (>60) with AML and NPM1 mutation ineligible for intensive chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 11:11:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA